Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 75 citing articles:

Cognitive impairment and type 2 diabetes mellitus: Focus of SGLT2 inhibitors treatment
Maria Rosaria Rizzo, Irene Di Meo, Rita Polito, et al.
Pharmacological Research (2022) Vol. 176, pp. 106062-106062
Open Access | Times Cited: 107
Association of Sodium–Glucose Cotransporter 2 Inhibitors With Time to Dementia: A Population-Based Cohort Study
Che‐Yuan Wu, Carina Iskander, Christa Wang, et al.
Diabetes Care (2022) Vol. 46, Iss. 2, pp. 297-304
Open Access | Times Cited: 79
Newer glucose‐lowering drugs and risk of dementia: A systematic review and meta‐analysis of observational studies
Huilin Tang, Hui Shao, C. Elizabeth Shaaban, et al.
Journal of the American Geriatrics Society (2023) Vol. 71, Iss. 7, pp. 2096-2106
Closed Access | Times Cited: 54
Sodium-glucose cotransporter-2 inhibitors and their potential role in dementia onset and cognitive function in patients with diabetes mellitus: a systematic review and meta-analysis
Y J Youn, Seung Yeon Kim, Hyun‐Jeong Jeong, et al.
Frontiers in Neuroendocrinology (2024) Vol. 73, pp. 101131-101131
Open Access | Times Cited: 23
Impact of Sodium Glucose Cotransporter 2 Inhibitors (SGLT2i) Therapy on Dementia and Cognitive Decline
Antonio Lardaro, L. Quarta, Stefania Pagnotta, et al.
Biomedicines (2024) Vol. 12, Iss. 8, pp. 1750-1750
Open Access | Times Cited: 18
Risk of dementia after initiation of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in adults aged 40-69 years with type 2 diabetes: population based cohort study
Anna Shin, Bo Kyung Koo, Jun Young Lee, et al.
BMJ (2024), pp. e079475-e079475
Open Access | Times Cited: 16
SGLT2 Inhibitor Use and Risk of Dementia and Parkinson Disease Among Patients With Type 2 Diabetes
Hae‐Kyung Kim, Geert Jan Biessels, Min Yu, et al.
Neurology (2024) Vol. 103, Iss. 8
Closed Access | Times Cited: 16
The Role of Inflammation, Oxidative Stress, Neuronal Damage, and Endothelial Dysfunction in the Neuropathology of Cognitive Complications in Diabetes: A Moderation and Mediation Analysis
Betül Sümbül Şekerci, Özge Pasin, Ezgi Balkan, et al.
Brain and Behavior (2025) Vol. 15, Iss. 1
Open Access | Times Cited: 2
Association between use of sodium-glucose co-transporter-2 inhibitor and the risk of incident dementia: a population-based cohort study
Zarin Abdullah, Ying Cui, Robert W. Platt, et al.
BMJ Open Diabetes Research & Care (2025) Vol. 13, Iss. 1, pp. e004541-e004541
Open Access | Times Cited: 2
Cognitive Impairment in Heart Failure: Landscape, Challenges, and Future Directions
Mengxi Yang, Di Sun, Yu Wang, et al.
Frontiers in Cardiovascular Medicine (2022) Vol. 8
Open Access | Times Cited: 49
Comparison of Sodium-Glucose Cotransporter-2 Inhibitor and Dipeptidyl Peptidase-4 Inhibitor on the Risks of New-Onset Atrial Fibrillation, Stroke and Mortality in Diabetic Patients: A Propensity Score-Matched Study in Hong Kong
Sharen Lee, Jiandong Zhou, Keith Sai Kit Leung, et al.
Cardiovascular Drugs and Therapy (2022) Vol. 37, Iss. 3, pp. 561-569
Open Access | Times Cited: 42
Hypoglycemic medicines in the treatment of Alzheimer’s disease: Pathophysiological links between AD and glucose metabolism
Yixuan Wang, Hao Hu, Xinyu Liu, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 36
Diabetes, antidiabetic medications and risk of dementia: A systematic umbrella review and meta‐analysis
Alvin Kuate Defo, Veselko Bakula, Alessandro Pisaturo, et al.
Diabetes Obesity and Metabolism (2023) Vol. 26, Iss. 2, pp. 441-462
Open Access | Times Cited: 31
The impact of diabetes in cognitive impairment: A review of current evidence and prospects for future investigations
Nicholas Aderinto, Gbolahan Olatunji, Muili Abdulbasit, et al.
Medicine (2023) Vol. 102, Iss. 43, pp. e35557-e35557
Open Access | Times Cited: 25
SGLT2 inhibitors: a novel therapy for cognitive impairment via multifaceted effects on the nervous system
Jiaqi Mei, Yi Li, Liyan Niu, et al.
Translational Neurodegeneration (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 15
Assessment of sodium-glucose cotransporter 2 inhibitors (SGLT2i) and other antidiabetic agents in Alzheimer’s disease: A population-based study
Mar Garcia-Zamora, Gemma García‐Lluch, Lucrecia Moreno, et al.
Pharmacological Research (2024) Vol. 206, pp. 107295-107295
Open Access | Times Cited: 13
Risk of Dementia in Patients with Diabetes Using Sodium-Glucose Transporter 2 Inhibitors (SGLT2i): A Systematic Review, Meta-Analysis, and Meta-Regression
Pricilla Yani Gunawan, Paskalis Andrew Gunawan, Timotius Ivan Hariyanto
Diabetes Therapy (2024) Vol. 15, Iss. 3, pp. 663-675
Open Access | Times Cited: 11
The impact of sodium‐glucose co‐transporter‐2 inhibitors on dementia and cardiovascular events in diabetic patients with atrial fibrillation
Yun‐Yu Chen, Hao‐Chih Chang, Yenn‐Jiang Lin, et al.
Diabetes/Metabolism Research and Reviews (2024) Vol. 40, Iss. 2
Open Access | Times Cited: 11
DPP-4 inhibition by linagliptin ameliorates age-related mild cognitive impairment by regulating microglia polarization in mice
Fen Zhuge, Liujie Zheng, Yuxiang Pan, et al.
Experimental Neurology (2024) Vol. 373, pp. 114689-114689
Closed Access | Times Cited: 10
Mitochondria and the Repurposing of Diabetes Drugs for Off-Label Health Benefits
Joyce Yip, Grace Shu Hui Chiang, I Lee, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 1, pp. 364-364
Open Access | Times Cited: 1
GLP-1RA and SGLT2i Medications for Type 2 Diabetes and Alzheimer Disease and Related Dementias
Huilin Tang, William T. Donahoo, Steven T. DeKosky, et al.
JAMA Neurology (2025)
Closed Access | Times Cited: 1
Metformin versus sulphonylureas for new onset atrial fibrillation and stroke in type 2 diabetes mellitus: a population-based study
Jiandong Zhou, Guoming Zhang, Carlin Chang, et al.
Acta Diabetologica (2022) Vol. 59, Iss. 5, pp. 697-709
Open Access | Times Cited: 31
Lower risk of gout in sodium glucose cotransporter 2 (SGLT2) inhibitors versus dipeptidyl peptidase-4 (DPP4) inhibitors in type-2 diabetes
Jiandong Zhou, Xuejin Liu, Oscar Hou In Chou, et al.
Lara D. Veeken (2022) Vol. 62, Iss. 4, pp. 1501-1510
Closed Access | Times Cited: 30
Efficacy and safety profile of SGLT2 inhibitors in the elderly: How is the benefit/risk balance?
André Scheen, Fabrice Bonnet
Diabetes & Metabolism (2023) Vol. 49, Iss. 2, pp. 101419-101419
Open Access | Times Cited: 20
Diabetes-Alzheimer's connection in older age: SGLT2 inhibitors as promising modulators of disease pathways
Francesca Mancinetti, Dionysios P. Xenos, Michelantonio De Fano, et al.
Ageing Research Reviews (2023) Vol. 90, pp. 102018-102018
Closed Access | Times Cited: 20
Page 1 - Next Page

Scroll to top